SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release second quarter ended June 30, 2007 financial results after the market closes on Tuesday, August 14, 2007. Cadence management will host a conference call and live webcast to discuss these financial results and provide a corporate overview on Tuesday, August 14, 2007 at 4:30 pm Eastern (1:30 pm Pacific).
Interested investors may participate in the conference call by dialing 888-802-2225 (domestic) or 913-312-1268 (international). To access the webcast, please log on to the company’s website at http://www.cadencepharm.com and go to the Investor Relations page and click on the link entitled “Events and Presentations” on the left side of the screen. The webcast will remain available on the company’s website until the next earnings call.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III products in development, including IV APAP (acetaminophen for injection) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence’s pipeline, visit http://www.cadencepharm.com.
Forward-Looking Statements
Cadence cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence’s business including, without limitation, the progress and timing of the company’s ongoing and planned clinical trials, difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products and other risks detailed in Cadence’s prior press releases as well as in Cadence’s public filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue Susan Neath SVP & Chief Financial Officer Media & Investor Relations Cadence Pharmaceuticals, Inc. Porter Novelli Life Sciences (619) 849-6007 Or Anna Gralinska Director, Investor Relations Cadence Pharmaceuticals, Inc. 858-436-1400
Cadence Pharmaceuticals, Inc.
CONTACT: William R. LaRue, SVP & Chief Financial Officer, or AnnaGralinska, Director of Investor Relations, both of Cadence Pharmaceuticals,Inc., 1-858-436-1400; or Susan Neath, Media & Investor Relations of PorterNovelli Life Sciences, +1-619-849-6007, for Cadence Pharmaceuticals, Inc.
Web site: http://www.cadencepharm.com/
